Low‑Dose Aspirin (81 mg) for Cardiovascular Disease Prevention

Secondary Prevention – Strong Recommendation (ACC/AHA)

• Aspirin 75–162 mg daily should be initiated and continued indefinitely in patients with established atherosclerotic cardiovascular disease (ASCVD). Strong recommendation. 1
• In patients with a prior myocardial infarction or acute coronary syndrome, low‑dose aspirin (75–100 mg) is indicated after completion of the initial dual‑antiplatelet therapy period. Strong recommendation. 2
• For individuals with a history of ischemic stroke or transient ischemic attack, aspirin 75–325 mg daily reduces recurrent events. Strong recommendation. 1
• Symptomatic peripheral artery disease warrants aspirin 75–325 mg daily to lower cardiovascular risk. Strong recommendation. 1

Primary Prevention – Conditional/Low‑Benefit Recommendations

• In adults aged 40–59 years with a 10‑year ASCVD risk ≥ 10 % (calculated with ACC/AHA Pooled Cohort Equations), low‑dose aspirin may be considered after shared decision‑making; the net benefit is modest. Grade C recommendation. 3
• For patients with diabetes plus at least one additional major risk factor (e.g., hypertension, dyslipidemia, smoking, family history of premature ASCVD, or albuminuria), aspirin may be considered for primary prevention. Grade C recommendation. 3

Optimal Dosing

• The recommended dose for both primary and secondary prevention is 75–100 mg daily (81 mg tablet in the United States). Strong recommendation. [4][2]
• The ADAPTABLE trial demonstrated no difference in cardiovascular outcomes or major bleeding between 81 mg and 325 mg daily, supporting the use of the lower dose. Evidence Level A. [4][2]
• Doses >100 mg increase gastrointestinal bleeding risk without providing additional cardiovascular benefit. Evidence Level B. 2
• In acute coronary syndrome, a loading dose of 162–325 mg is given initially, followed by maintenance of 75–100 mg daily. Evidence Level B. 2

Bleeding Risk Quantification

• Aspirin raises the relative risk of major bleeding by ≈ 60 % (RR 1.6), corresponding to 2–4 extra major gastrointestinal bleeds per 1,000 middle‑aged adults over 5 years. Evidence Level B. 5
• In real‑world practice, major bleeding occurs at about 5 events per 1,000 patients per year. Evidence Level C. 2

Absolute Contraindications (ACC/AHA)

• Age > 70 years for primary prevention. 3
• History of gastrointestinal ulcer or recent bleeding. 3
• Uncontrolled hypertension. Evidence Level C. 4
• Concurrent use of anticoagulants (warfarin, DOACs) or chronic NSAIDs. Evidence Level C. 4
• Active hepatic disease or bleeding disorder. Evidence Level B. 5
• Anemia or chronic kidney disease. 3
• Age < 21 years (risk of Reye syndrome). Evidence Level C. 6
• Documented aspirin allergy. Evidence Level A. 1

Alternative Antiplatelet Therapy

• For patients with a confirmed aspirin allergy who require antiplatelet therapy, clopidogrel 75 mg daily is recommended as a substitute. Strong recommendation. 1

Dual Antiplatelet Therapy After ACS or PCI

• Following acute coronary syndrome or percutaneous coronary intervention with stent placement, combine low‑dose aspirin (75–100 mg daily) with a P2Y12 inhibitor (clopidogrel 75 mg, prasugrel 10 mg, or ticagrelor 90 mg twice daily) for at least 12 months. Strong recommendation. 1

Summary of Evidence on Efficacy

• Meta‑analyses show aspirin reduces non‑fatal myocardial infarction by ≈ 26 % but has minimal impact on cardiovascular mortality (RR 0.95). Evidence Level B. 6
• Sex‑specific effects: in primary prevention, aspirin lowers myocardial infarction risk in men but not women, whereas it reduces stroke risk in women but not men. Evidence Level B. 6

Aspirin Use in Adults ≥ 70 Years Old

Secondary Prevention (Established ASCVD)

• Continue low‑dose aspirin (81 mg daily) indefinitely for patients with documented atherosclerotic cardiovascular disease (prior myocardial infarction, stroke, percutaneous coronary intervention, coronary artery bypass grafting, or significant coronary artery disease on imaging). The American Diabetes Association (2022) recommends this regimen, noting that the benefits in reducing recurrent cardiovascular events outweigh bleeding risks. Strong evidence (multiple randomized trials) supports this recommendation. 7

• An 81 mg dose is evidence‑based and as effective as higher doses (e.g., 325 mg) with a lower bleeding profile. The ADAPTABLE trial, cited by the ADA 2022 guideline, demonstrated comparable efficacy of low‑dose aspirin with reduced hemorrhagic complications. Strong evidence. 7

Primary Prevention (No Prior ASCVD)

• Discontinue aspirin in patients ≥ 70 years without a history of cardiovascular events. The ADA 2022 guideline states that, in this age group, the balance of risk versus benefit favors harm, and aspirin should not be initiated for primary prevention. Strong evidence against use. 7

• For patients ≥ 70 years, even those with diabetes, aspirin is generally not recommended for primary prevention. The 2022 ADA guidelines explicitly note that age > 70 shifts the benefit‑risk balance toward greater bleeding risk, making routine aspirin use inappropriate despite high cardiovascular risk. Moderate‑to‑strong evidence. 7

• The 2019 ADA guideline reinforces that, in older adults, the potential cardiovascular benefit of aspirin is outweighed by bleeding risk, and discontinuation should be considered. Moderate evidence. 8

Diabetes‑Specific Considerations

• In patients with diabetes who are ≥ 70 years old, aspirin should not be used for primary prevention. The 2022 ADA recommendations highlight that age‑related bleeding risk supersedes any modest cardiovascular benefit, even in the presence of diabetes‑related risk factors. Moderate‑to‑strong evidence. 7

Evidence Strength & Guideline Context

• Age > 70 years is identified by the American Diabetes Association (2022) as a critical threshold where gastrointestinal and other major bleeding risks increase substantially while cardiovascular benefits of aspirin diminish. This reflects strong evidence from recent large‑scale trials and meta‑analyses. 7

Clinical Pitfalls & Reassessment

• Many older patients were started on aspirin under pre‑2019 guidelines that were more permissive for primary prevention. The 2019 ADA guideline advises clinicians to reassess bleeding risk regularly and discontinue aspirin when new risk factors emerge. Moderate evidence. 8

• Even when diabetes is present with additional risk factors, age > 70 years makes aspirin inappropriate for primary prevention. The 2022 ADA guideline emphasizes that the modest (~12 %) reduction in cardiovascular events does not justify the heightened bleeding hazard in this population. Moderate‑to‑strong evidence. 7